CUSIP No. 038505301
|
SCHEDULE 13D/A
|
Page 2 of 6 Pages
|
1
|
NAME OF REPORTING PERSON
First Eagle Investment Management, LLC
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☒
(b) ☐
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
AF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: |
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
4,210,186 shares of Common Stock*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
4,210,186 shares of Common Stock*
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
4,210,186 shares of Common Stock*
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.31%*
|
|||
14
|
TYPE OF REPORTING PERSON
IA; CO
|
|||
|
|
|
|
|
* Includes 575,815 shares of Common Stock issuable upon the conversion of the 9.0% Senior Convertible Notes due 2021 of the Issuer (the "Convertible Notes") and 259,117 shares of Common Stock issuable upon exercise of warrants to purchase shares of Common Stock of the Issuer (the "Warrants").
|
CUSIP No. 038505301
|
SCHEDULE 13D/A
|
Page 3 of 6 Pages
|
1
|
NAME OF REPORTING PERSON
First Eagle Value in Biotechnology Master Fund, Ltd.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☒
(b) ☐
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
WC
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
|||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: |
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
2,217,899 shares of Common Stock*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
2,217,899 shares of Common Stock*
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,217,899 shares of Common Stock *
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.36%*
|
|||
14
|
TYPE OF REPORTING PERSON
CO
|
|||
|
|
|
|
|
CUSIP No. 038505301
|
SCHEDULE 13D/A
|
Page 4 of 6 Pages
|
1
|
NAME OF REPORTING PERSON
21 April Fund, Ltd.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ☒
(b) ☐
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
WC
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
☐
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
|||
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: |
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
1,554,141 shares of Common Stock *
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
1,554,141 shares of Common Stock *
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
1,554,141 shares of Common Stock *
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
☐
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.96%*
|
|||
14
|
TYPE OF REPORTING PERSON
CO
|
|||
|
|
|
|
|
CUSIP No. 038505301
|
SCHEDULE 13D/A
|
Page 5 of 6 Pages
|
Item 6.
|
CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
|
CUSIP No. 038505301
|
SCHEDULE 13D/A
|
Page 6 of 6 Pages
|
|
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
|
|
|
|
|
|
|
|
|
/s/ Michael M. Kellen
|
|
|
Name: Michael M. Kellen
|
|
|
Title: Director
|
|
|
|
|
|
|
|
|
FIRST EAGLE VALUE IN BIOTECHNOLOGY MASTER
FUND, LTD. |
|
|
|
|
|
By: FIRST EAGLE INVESTMENT MANAGEMENT, LLC,
Its Investment Adviser
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael M. Kellen
|
|
|
Name: Michael M. Kellen
|
|
|
Title: Director
|
|
|
|
|
|
|
|
21 APRIL FUND, LTD.
|
|
|
|
|
|
By: FIRST EAGLE INVESTMENT MANAGEMENT, LLC,
Its Investment Adviser
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael M. Kellen
|
|
|
Name: Michael M. Kellen
|
|
|
Title: Director
|
|
|
|
|
|